Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that helps the patient’s T-cells become efficient at destroying the cancer. For some DLBCL patients, it has cured their cancer.
The CAR T-cell therapy called Yescarta (axicabtagene ciloleucel) is FDA-approved for DLBCL patients as:
“CAR T-cell therapies are customized for each individual patient. They are made by collecting T-cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells."
Patients are monitored for a few days at the clinic following treatment to review if side effect treatment is needed related to cytokine release syndrome or neurological symptoms. Some patients may experience these side effects, however, most patients recover quickly with the help of in-clinic side-effect solution medicines. Researchers are also continuing to study more ways to help CAR T-cell therapy be more effective with fewer side effects.
Talk with your DLBCL specialist to see if joining a CAR T-cell clinical trial is right for you. Need help finding a DLBCL specialist? Visit HealthTree’s DLBCL Specialist Directory.
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that helps the patient’s T-cells become efficient at destroying the cancer. For some DLBCL patients, it has cured their cancer.
The CAR T-cell therapy called Yescarta (axicabtagene ciloleucel) is FDA-approved for DLBCL patients as:
“CAR T-cell therapies are customized for each individual patient. They are made by collecting T-cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells."
Patients are monitored for a few days at the clinic following treatment to review if side effect treatment is needed related to cytokine release syndrome or neurological symptoms. Some patients may experience these side effects, however, most patients recover quickly with the help of in-clinic side-effect solution medicines. Researchers are also continuing to study more ways to help CAR T-cell therapy be more effective with fewer side effects.
Talk with your DLBCL specialist to see if joining a CAR T-cell clinical trial is right for you. Need help finding a DLBCL specialist? Visit HealthTree’s DLBCL Specialist Directory.
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family, sewing, and cooking.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.